Therapeutic Metastatic Prostate Cancer Vaccines: Lessons Learnt from Urologic Oncology

Overview

Journal Cent European J Urol

Specialty Urology

Date 2021 Nov 3

PMID 34729217

Citations 7

Authors

Witold Lasek

Lukasz Zapala

Affiliations

Soon will be listed here.

Abstract

Introduction: Therapeutic cancer vaccines have been recognized as a promising treatment option in clinical oncology for nearly three decades. However, despite many efforts, only one cancer vaccine - sipuleucel-T, activating the anti-PAP (prostatic acid phosphatase) immune response, has obtained Food and Drug Administration (FDA) approval.

Material And Methods: This review describes the most advanced research on the use of therapeutic cancer vaccines in the treatment of prostate cancer.

Results: In addition to sipuleucel-T, which was approved in urologic oncology in 2010, four cancer vaccines were and have been tested in phase III clinical trials in patients with metastatic castration resistant prostate cancer (mCRPC): GVAX (prostate cancer variant) containing irradiated prostate cancer cell, PPV peptide vaccine, PCVAC/PCa dendritic cell-based vaccine and PROSTVAC anti PSA (prostate-specific antigen) vaccine. This review compares the most promising and best-studied cancer vaccines: sipuleucel-T and PROSTVAC. Currently, both vaccines have been tested in combination with other therapeutic approaches, including check point inhibitors.

Conclusions: It seems possible that the efficacy of sipuleucel-T and PROSTVAC could be increased in combination therapy with other medications.

Citing Articles

Insights into immuno-oncology drug development landscape with focus on bone metastasis.

Kahkonen T, Halleen J, MacRitchie G, Andersson R, Bernoulli J Front Immunol. 2023; 14:1121878.

PMID: 37475868 PMC: 10355372. DOI: 10.3389/fimmu.2023.1121878.

Advances in bio-immunotherapy for castration-resistant prostate cancer.

Lin C, Chen Y, Shi L, Lin H, Xia H, Yin W J Cancer Res Clin Oncol. 2023; 149(14):13451-13458.

PMID: 37460807 DOI: 10.1007/s00432-023-05152-9.

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives.

Rehman L, Nisar M, Fatima W, Sarfraz A, Azeem N, Sarfraz Z J Clin Med. 2023; 12(4).

PMID: 36835981 PMC: 9966657. DOI: 10.3390/jcm12041446.

Boosting the Immune Response-Combining Local and Immune Therapy for Prostate Cancer Treatment.

Karwacki J, Kielbik A, Szlasa W, Sauer N, Kowalczyk K, Krajewski W Cells. 2022; 11(18).

PMID: 36139368 PMC: 9496996. DOI: 10.3390/cells11182793.

Cancer Immunotherapy and Delivery System: An Update.

Yang M, Olaoba O, Zhang C, Kimchi E, Staveley-OCarroll K, Li G Pharmaceutics. 2022; 14(8).

PMID: 36015256 PMC: 9413869. DOI: 10.3390/pharmaceutics14081630.

References

Prasad V, Berger V . Hard-Wired Bias: How Even Double-Blind, Randomized Controlled Trials Can Be Skewed From the Start. Mayo Clin Proc. 2015; 90(9):1171-5. PMC: 4567484. DOI: 10.1016/j.mayocp.2015.05.006. View

Sfakianos J, Salome B, Daza J, Farkas A, Bhardwaj N, Horowitz A . Bacillus Calmette-Guerin (BCG): Its fight against pathogens and cancer. Urol Oncol. 2020; 39(2):121-129. DOI: 10.1016/j.urolonc.2020.09.031. View

Gonzalez H, Hagerling C, Werb Z . Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018; 32(19-20):1267-1284. PMC: 6169832. DOI: 10.1101/gad.314617.118. View

Jiang T, Zhou C, Ren S . Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016; 5(6):e1163462. PMC: 4938354. DOI: 10.1080/2162402X.2016.1163462. View

Kantoff P, Gulley J, Pico-Navarro C . Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2016; 35(1):124-125. PMC: 6411419. DOI: 10.1200/JCO.2016.69.7748. View

Kantoff P, Schuetz T, Blumenstein B, Glode L, Bilhartz D, Wyand M . Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010; 28(7):1099-105. PMC: 2834462. DOI: 10.1200/JCO.2009.25.0597. View

Halabi S, Small E, Kantoff P, Kattan M, Kaplan E, Dawson N . Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003; 21(7):1232-7. DOI: 10.1200/JCO.2003.06.100. View

Gulley J, Borre M, Vogelzang N, Ng S, Agarwal N, Parker C . Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019; 37(13):1051-1061. PMC: 6494360. DOI: 10.1200/JCO.18.02031. View

Drake C . Update on prostate cancer vaccines. Cancer J. 2011; 17(5):294-9. PMC: 3420819. DOI: 10.1097/PPO.0b013e3182325e78. View

10.

Handa S, Hans B, Goel S, Bashorun H, Dovey Z, Tewari A . Immunotherapy in prostate cancer: current state and future perspectives. Ther Adv Urol. 2020; 12:1756287220951404. PMC: 7476347. DOI: 10.1177/1756287220951404. View

11.

Lasek W, Zagozdzon R, Jakobisiak M . Interleukin 12: still a promising candidate for tumor immunotherapy?. Cancer Immunol Immunother. 2014; 63(5):419-35. PMC: 3994286. DOI: 10.1007/s00262-014-1523-1. View

12.

Kienle G . Fever in Cancer Treatment: Coley's Therapy and Epidemiologic Observations. Glob Adv Health Med. 2013; 1(1):92-100. PMC: 3833486. DOI: 10.7453/gahmj.2012.1.1.016. View

13.

Geary S, Salem A . Prostate cancer vaccines: Update on clinical development. Oncoimmunology. 2013; 2(5):e24523. PMC: 3667918. DOI: 10.4161/onci.24523. View

14.

Kantoff P, Mohler J . New developments in the management of prostate cancer. J Natl Compr Canc Netw. 2013; 11(5 Suppl):653-7. DOI: 10.6004/jnccn.2013.0194. View

15.

Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J . Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014; 106(11). PMC: 4241888. DOI: 10.1093/jnci/dju268. View

16.

Noguchi M, Fujimoto K, Arai G, Uemura H, Hashine K, Matsumoto H . A randomized phase III trial of personalized peptide vaccination for castration‑resistant prostate cancer progressing after docetaxel. Oncol Rep. 2020; 45(1):159-168. PMC: 7709822. DOI: 10.3892/or.2020.7847. View

17.

Sater H, Marte J, Donahue R, Walter-Rodriguez B, Heery C, Steinberg S . Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer. J Immunother Cancer. 2020; 8(1). PMC: 7174144. DOI: 10.1136/jitc-2020-000655. View

18.

Hu Z, Ott P, Wu C . Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2017; 18(3):168-182. PMC: 6508552. DOI: 10.1038/nri.2017.131. View

19.

Higano C, Schellhammer P, Small E, Burch P, Nemunaitis J, Yuh L . Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009; 115(16):3670-9. DOI: 10.1002/cncr.24429. View

20.

Zapala L, Wolny R, Wachowska M, Jakobisiak M, Lasek W . Synergistic antitumor effect of JAWSII dendritic cells and interleukin 12 in a melanoma mouse model. Oncol Rep. 2012; 29(3):1208-14. DOI: 10.3892/or.2012.2193. View